Enhanced relaxation to the Rho-kinase inhibitor Y-27632 in mesenteric arteries from mineralocorticoid hypertensive rats

Davis S. Weber, R Clinton Webb

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Increased vasoconstriction is characteristic of hypertension. In this study, we tested the hypothesis that changes in vascular responses during mineralocorticoid hypertension may be due to increased activation of the Rho/Rho-kinase pathway. To test this, relaxation responses to the Rho-kinase inhibitor Y-27632 were determined by measuring isometric force in deendothelialized mesenteric arteries from mineralocorticoid-hypertensive rats and sham-operated controls. Following agonist-induced contraction by serotonin (5-HT, 5-hydroxytryptamine), arteries from hypertensive rats demonstrated a greater relaxation to the Rho-kinase inhibitor Y-27632 (65 ± 5% vs.28 ± 10%). Treatment with an EC50 concentration of Y-27632 following a KCl-induced contraction caused minimal relaxation of arteries in both groups of animals. These findings suggest that augmented Rho-kinase activity in the vasculature of mineralocorticoid hypertensive rats may contribute to the enhanced vascular reactivity of agonist-mediated stimuli characteristic of this model of hypertension.

Original languageEnglish (US)
Pages (from-to)129-133
Number of pages5
JournalPharmacology
Volume63
Issue number3
DOIs
StatePublished - Dec 1 2001

Fingerprint

rho-Associated Kinases
Mineralocorticoids
Mesenteric Arteries
Hypertension
Blood Vessels
Serotonin
Arteries
Vasoconstriction
Y 27632

Keywords

  • 5-Hydroxytryptamine
  • DOCA-salt hypertension
  • p160ROCK

ASJC Scopus subject areas

  • Pharmacology

Cite this

Enhanced relaxation to the Rho-kinase inhibitor Y-27632 in mesenteric arteries from mineralocorticoid hypertensive rats. / Weber, Davis S.; Webb, R Clinton.

In: Pharmacology, Vol. 63, No. 3, 01.12.2001, p. 129-133.

Research output: Contribution to journalArticle

@article{b3c28f6b4a344d9c9f9c03b4cde13633,
title = "Enhanced relaxation to the Rho-kinase inhibitor Y-27632 in mesenteric arteries from mineralocorticoid hypertensive rats",
abstract = "Increased vasoconstriction is characteristic of hypertension. In this study, we tested the hypothesis that changes in vascular responses during mineralocorticoid hypertension may be due to increased activation of the Rho/Rho-kinase pathway. To test this, relaxation responses to the Rho-kinase inhibitor Y-27632 were determined by measuring isometric force in deendothelialized mesenteric arteries from mineralocorticoid-hypertensive rats and sham-operated controls. Following agonist-induced contraction by serotonin (5-HT, 5-hydroxytryptamine), arteries from hypertensive rats demonstrated a greater relaxation to the Rho-kinase inhibitor Y-27632 (65 ± 5{\%} vs.28 ± 10{\%}). Treatment with an EC50 concentration of Y-27632 following a KCl-induced contraction caused minimal relaxation of arteries in both groups of animals. These findings suggest that augmented Rho-kinase activity in the vasculature of mineralocorticoid hypertensive rats may contribute to the enhanced vascular reactivity of agonist-mediated stimuli characteristic of this model of hypertension.",
keywords = "5-Hydroxytryptamine, DOCA-salt hypertension, p160ROCK",
author = "Weber, {Davis S.} and Webb, {R Clinton}",
year = "2001",
month = "12",
day = "1",
doi = "10.1159/000056123",
language = "English (US)",
volume = "63",
pages = "129--133",
journal = "Pharmacology",
issn = "0031-7012",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Enhanced relaxation to the Rho-kinase inhibitor Y-27632 in mesenteric arteries from mineralocorticoid hypertensive rats

AU - Weber, Davis S.

AU - Webb, R Clinton

PY - 2001/12/1

Y1 - 2001/12/1

N2 - Increased vasoconstriction is characteristic of hypertension. In this study, we tested the hypothesis that changes in vascular responses during mineralocorticoid hypertension may be due to increased activation of the Rho/Rho-kinase pathway. To test this, relaxation responses to the Rho-kinase inhibitor Y-27632 were determined by measuring isometric force in deendothelialized mesenteric arteries from mineralocorticoid-hypertensive rats and sham-operated controls. Following agonist-induced contraction by serotonin (5-HT, 5-hydroxytryptamine), arteries from hypertensive rats demonstrated a greater relaxation to the Rho-kinase inhibitor Y-27632 (65 ± 5% vs.28 ± 10%). Treatment with an EC50 concentration of Y-27632 following a KCl-induced contraction caused minimal relaxation of arteries in both groups of animals. These findings suggest that augmented Rho-kinase activity in the vasculature of mineralocorticoid hypertensive rats may contribute to the enhanced vascular reactivity of agonist-mediated stimuli characteristic of this model of hypertension.

AB - Increased vasoconstriction is characteristic of hypertension. In this study, we tested the hypothesis that changes in vascular responses during mineralocorticoid hypertension may be due to increased activation of the Rho/Rho-kinase pathway. To test this, relaxation responses to the Rho-kinase inhibitor Y-27632 were determined by measuring isometric force in deendothelialized mesenteric arteries from mineralocorticoid-hypertensive rats and sham-operated controls. Following agonist-induced contraction by serotonin (5-HT, 5-hydroxytryptamine), arteries from hypertensive rats demonstrated a greater relaxation to the Rho-kinase inhibitor Y-27632 (65 ± 5% vs.28 ± 10%). Treatment with an EC50 concentration of Y-27632 following a KCl-induced contraction caused minimal relaxation of arteries in both groups of animals. These findings suggest that augmented Rho-kinase activity in the vasculature of mineralocorticoid hypertensive rats may contribute to the enhanced vascular reactivity of agonist-mediated stimuli characteristic of this model of hypertension.

KW - 5-Hydroxytryptamine

KW - DOCA-salt hypertension

KW - p160ROCK

UR - http://www.scopus.com/inward/record.url?scp=0035742442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035742442&partnerID=8YFLogxK

U2 - 10.1159/000056123

DO - 10.1159/000056123

M3 - Article

C2 - 11598417

AN - SCOPUS:0035742442

VL - 63

SP - 129

EP - 133

JO - Pharmacology

JF - Pharmacology

SN - 0031-7012

IS - 3

ER -